Colorectal cancer (CRC) is one of the most common neoplasms accompanied by a high rate of morbidity and mortality, immune checkpoint molecules have been identified as a novel treatment for CRC, such as PD-1 and PD-L1 (131, 132). This evidence concerns the gene CD274 and colorectal carcinoma.